Memphasys(MEM.AU),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

MEM.AU Memphasys

Closed 04-29 16:12:00 AEST

0.01

+0.00

0.00%

High0.01	Low0.01	Vol950.00
Open0.01	D1 Closing0.01	Amplitude0.00%
Mkt Cap9.92M	Tradable Cap6.16M	Total Shares1.98B
T/O5.00	T/O Rate0.00%	Tradable Shares1.23B
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

Invest in Global Markets with Tiger Brokers!

Open App

{"stockData":{"symbol":"MEM.AU","market":"AU","secType":"STK","nameCN":"Memphasys","latestPrice":0.005,"timestamp":1745907120000,"preClose":0.005,"halted":0,"volume":950,"delay":0,"nameEN":"Memphasys","floatShares":1232899646,"shares":1983598100,"eps":-0.002883,"marketStatus":"Closed","change":0,"latestTime":"04-29 16:12:00 AEST","open":0.005,"high":0.005,"low":0.005,"amount":5,"amplitude":0,"askPrice":0.006,"askSize":10082446,"bidPrice":0.005,"bidSize":1499999,"shortable":3,"etf":0,"ttmEps":-0.002883,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":0,"beginTime":1745971200000},"marketStatusCode":5,"adr":0,"exchange":"ASX","adjPreClose":0.005,"openAndCloseTimeList":[[1745884800000,1745906400000]],"volumeRatio":0.000141,"lotSize":1,"tradeCurrency":"AUD"},"requestUrl":"/m/hq/s/MEM.AU/tweets","defaultTab":"tweets","newsList":[{"id":"2526032734","title":"BRIEF-Memphasys Seeks Trading Halt","url":"https://stock-news.laohu8.com/highlight/detail?id=2526032734","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526032734?lang=en_us&edition=full_marsco","pubTime":"2025-04-10 09:34","pubTimestamp":1744248867,"startTime":"0","endTime":"0","summary":"BRIEF-Memphasys Seeks Trading HaltApril 10 (Reuters) - Memphasys Ltd MEM.AX:SEEKS TRADING HALT PENDING ANNOUNCEMENT ON PROPOSED CAPITAL RAISINGFurther company coverage: MEM.AX ((Reuters.Briefs@thomsonreuters.com;))","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250410:nFWN3QN1B4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MEM.AU","BK7048"],"gpt_icon":0},{"id":"2526220393","title":"Memphasys Ltd -  Seeks Trading Halt Pending Announcement on Proposed Capital Raising","url":"https://stock-news.laohu8.com/highlight/detail?id=2526220393","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526220393?lang=en_us&edition=full_marsco","pubTime":"2025-04-10 09:33","pubTimestamp":1744248836,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250410:nFWN3QN1B4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["MEM.AU","BK7048"],"gpt_icon":0},{"id":"2526519342","title":"Memphasys Ltd-Proposed Issue of Securities - Mem","url":"https://stock-news.laohu8.com/highlight/detail?id=2526519342","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526519342?lang=en_us&edition=full_marsco","pubTime":"2025-04-10 06:20","pubTimestamp":1744237214,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250409:nTUEBVQV5J:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7048","MEM.AU"],"gpt_icon":0},{"id":"2524440297","title":"Memphasys Ltd-Roxsta Offers Effective Oxidative Stress Measurem't 4 Cattle","url":"https://stock-news.laohu8.com/highlight/detail?id=2524440297","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524440297?lang=en_us&edition=full_marsco","pubTime":"2025-04-03 06:53","pubTimestamp":1743634439,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250402:nTUE9LCB5N:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["MEM.AU","BK7048"],"gpt_icon":0},{"id":"2521568759","title":"Memphasys achieves key milestone with clinical validation of Felix fertility device","url":"https://stock-news.laohu8.com/highlight/detail?id=2521568759","media":"Small Caps","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521568759?lang=en_us&edition=full_marsco","pubTime":"2025-03-24 11:49","pubTimestamp":1742788164,"startTime":"0","endTime":"0","summary":"Memphasys  has published positive data from a pivotal clinical trial of its Felix electrophoresis-based sperm separation device for use in assisted reproduction.The trial validated the ability of the Felix device to meet and exceed industry benchmarks and found it to be non-inferior to the “swim-up” technique but statistically superior to DGC , the world’s most commonly used sperm preparation method.The company conducted the trial, which confirmed the device to have best-in-class performance in sperm selection for human fertility treatments, in partnership with Perth-based clinic Monash IVF Australia.Felix also demonstrated a positive primary endpoint of improved embryo utilisation compared with swim-up and DGC.Specifically, the number of embryos utilised divided by the total number of embryos created, a benchmark of assisted reproduction cycle success.Memphasys chief executive officer David Ali said the Felix trial was the most rigorous study ever conducted for a sperm separation devi","market":"hk","thumbnail":"https://cdn.shortpixel.ai/client/w_868,q_lossy,to_auto,ret_wait/https://150309019.v2.pressablecdn.com/wp-content/uploads/2025/03/Memphasys-ASX-MEM-Felix-Clinical-Trial-Confirms-Best-in-Class-Performance.jpg","type":0,"news_type":0,"thumbnails":["https://cdn.shortpixel.ai/client/w_868,q_lossy,to_auto,ret_wait/https://150309019.v2.pressablecdn.com/wp-content/uploads/2025/03/Memphasys-ASX-MEM-Felix-Clinical-Trial-Confirms-Best-in-Class-Performance.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://smallcaps.com.au/memphasys-clinical-validation-felix-fertility-device/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"smallcap_stock","symbols":["MEM.AU","BK7048","MEM"],"gpt_icon":0},{"id":"2521174730","title":"BUZZ-Australia's Memphasys soars on upbeat trial results for sperm selection device","url":"https://stock-news.laohu8.com/highlight/detail?id=2521174730","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521174730?lang=en_us&edition=full_marsco","pubTime":"2025-03-24 11:03","pubTimestamp":1742785390,"startTime":"0","endTime":"0","summary":"BUZZ-Australia's Memphasys soars on upbeat trial results for sperm selection device** Memphasys MEM.AX soars as much as 57.1% to A$0.011, set for biggest intraday gain since August 18, 2022** Stock hits highest since January 6** Medical devices maker reports positive clinical trial results for its Felix sperm selection system** Says results exceed industry benchmarks in sperm selection for assisted reproductive technology** Stock logs busiest trading day since October 2018, with ~50.3 mln shares traded vs 30-day avg of ~1.8 mln** MEM last up ~43%, extends YTD gains to 25%  ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250324:nL3N3Q706V:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7048","MEM.AU"],"gpt_icon":0},{"id":"2521734542","title":"Monday’s HotCopper Trends: Opthea strife, Errawarra jumps on acquisitions, Memphasys best-in-class trial results | March 21, 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2521734542","media":"The Market Herald","labels":["merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521734542?lang=en_us&edition=full_marsco","pubTime":"2025-03-24 10:13","pubTimestamp":1742782380,"startTime":"0","endTime":"0","summary":"The ASX has been trading flat at around 7,928 points.Discretionary has been the best performing sector today, up 1%, followed by Financials, up 0.66%, and Utilities, up 0.5%.Staples has been the worst performing, down 1%, followed by Materials, down 0.9%, and Industrials, down 0.8%.Opthea  has been the most watched on HotCopper forums today and is in a trading halt. Its COAST Phase 3 trial failed to meet primary endpoint of mean change in best corrected visual acuity from baseline to Week 52. The company is now considering the overall impact of the negative trial result heading into the year.Also trending: Errawarra Resources , which has entered binding agreements to acquire 70% of the historical Elizabeth Hill Silver Project, 70% of the silver rights to the Pinderi Hills Project tenement package, and 70% of the ownership of three tenements surrounding the silver project.Rounding out the most discussed has been Memphasys , which unveiled the successful unblinding and data analysis of i","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://themarketonline.com.au/mondays-hotcopper-trends-opthea-strife-errawarra-jumps-on-acquisitions-memphasys-best-in-class-trial-results-march-21-2025-2025-03-24/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"merge","news_rank":0,"length":0,"strategy_id":0,"source":"markerherald_stock","symbols":["MEM.AU","BK7508","OPT.AU","ERW.AU","BK7095","OPT","BK7067","BK7048","MEM"],"gpt_icon":0},{"id":"2521102733","title":"Memphasys tech: Trial results prove it lifts the guys’ game in IVF","url":"https://stock-news.laohu8.com/highlight/detail?id=2521102733","media":"The Market Herald","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521102733?lang=en_us&edition=full_marsco","pubTime":"2025-03-24 07:07","pubTimestamp":1742771220,"startTime":"0","endTime":"0","summary":"Reproductive technology developed by Memphasys  is proving to be a gamechanger in addressing the men’s side of infertility – which is now understood to cause at least half of all conception issues.The company’s Felix System has successfully completed its Phase III clinical trial, proving it works faster than traditional methods, without adverse effects, and with scientists preferring it over the most widely used traditional IVF technologies.Memphasys reached its primary endpoint comparing its Embryo Utilisation Rateagainst existing Density Gradient Centrifugation  and Swim-Up IVF techniques.The trial has proven Felix is as good as the Swim-Up technique and “superior” to the world’s most used DGC method. And, Felix has other benefits in relation to both existing methods, which I’ll run through shortly.Memphasys partnered with Monash IVF Group , another Australian reproductive and fertility services company, for the trials.It’s in this male reproduction side where Memphasys is positioned","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://themarketonline.com.au/memphasys-tech-trial-results-prove-it-lifts-the-guys-game-in-ivf-2025-03-24/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"markerherald_stock","symbols":["ART.AU","BK7508","MVF.AU","MEM.AU","MEM","BK7048","BK7113","UAE","BK7002"],"gpt_icon":0},{"id":"2520190840","title":"BRIEF-Memphasys Seeks Trading Halt","url":"https://stock-news.laohu8.com/highlight/detail?id=2520190840","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520190840?lang=en_us&edition=full_marsco","pubTime":"2025-03-20 06:18","pubTimestamp":1742422703,"startTime":"0","endTime":"0","summary":"BRIEF-Memphasys Seeks Trading HaltMarch 20 (Reuters) - Memphasys Ltd MEM.AX:SEEKS TRADING HALT PENDING ANNOUNCEMENT ON  FELIX SYSTEM CLINICAL TRIAL RESULTSFurther company coverage: MEM.AX ((Reuters.Briefs@thomsonreuters.com;))","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250319:nFWN3Q213D:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7048","MEM.AU"],"gpt_icon":0},{"id":"2516572818","title":"Here's Why Memphasys (ASX:MEM) Can Afford Some Debt","url":"https://stock-news.laohu8.com/highlight/detail?id=2516572818","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516572818?lang=en_us&edition=full_marsco","pubTime":"2025-03-03 07:33","pubTimestamp":1740958437,"startTime":"0","endTime":"0","summary":"Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it seems the smart money knows that...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/9551728-choice2-main-header/1585186774276","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/9551728-choice2-main-header/1585186774276"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-mem/memphasys-shares/news/heres-why-memphasys-asxmem-can-afford-some-debt","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["MEM","BK7048","MEM.AU","EBIT"],"gpt_icon":0},{"id":"2512652289","title":"Memphasys expands into Brazil with Felix System trials","url":"https://stock-news.laohu8.com/highlight/detail?id=2512652289","media":"Grafa","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2512652289?lang=en_us&edition=full_marsco","pubTime":"2025-02-17 08:10","pubTimestamp":1739751011,"startTime":"0","endTime":"0","summary":"Memphasys , a bio-separations and reproductive biotechnology company, has initiated its commercial endeavours in Brazil.The venture includes a collaboration with Laboratorio Androscience, a notable Brazilian andrology clinic, for clinical utility testing of Memphasys' Felix System in the IVF sector.The testing, which commenced recently, involves deploying a Felix console and 20 cartridges over three months.The phase aims to evaluate the system's efficiency compared to existing sperm preparation processes, including clinician training.\"Entering the Brazilian and potentially Latin American markets presents a significant commercial opportunity for Memphasys,\" said David Ali, Managing Director of Memphasys.Acclaimed Brazilian andrologist, Dr. Jorge Hallak, is spearheading the trial at Laboratorio Androscience, focusing on men with male infertility and substandard semen quality.Dr. Hallak and Memphasys' Scientific Director, Laureate Professor John Aitken, are expected to present findings at","market":null,"thumbnail":"https://images.grafa.com/grafa/media-health-memphasys-expands-into-brazil-with-felix-system-trials-375001-638753478112047113.jpeg","type":0,"news_type":0,"thumbnails":["https://images.grafa.com/grafa/media-health-memphasys-expands-into-brazil-with-felix-system-trials-375001-638753478112047113.jpeg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://grafa.com/news/health-memphasys-expands-into-brazil-with-felix-system-trials-375001?referralcode=A314DFDBE96C354756A893C6E3E02493","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7048","MEM.AU"],"gpt_icon":0},{"id":"2510878158","title":"Memphasys Completes Felix System Clinical Trial, Shares Rise Past 14%","url":"https://stock-news.laohu8.com/highlight/detail?id=2510878158","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2510878158?lang=en_us&edition=full_marsco","pubTime":"2025-02-11 15:00","pubTimestamp":1739257236,"startTime":"0","endTime":"0","summary":"Memphasys  completed a clinical trial of its advanced sperm selection technology, Felix System, for assisted reproductive technology procedures, according to a Tuesday Australian bourse filing.It achieved the last patient visit in the trial, with all required patient visits, including pregnancy outcomes completed, the filing said.Data lock is anticipated in around two weeks, following a final data clean-up, management, and source verification phase.It will use the trial data as part of its ongoing CE Mark submission to advanced commercialization activities in Europe. Regulatory approvals in Australia and India are expected to follow soon after.The firm's shares rose past 14% on market close on Tuesday.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["MEM.AU","XAO.AU","BK7048","MEM","XKO.AU","XJO.AU"],"gpt_icon":0},{"id":"2504290702","title":"Memphasys highlights RoXsta’s diagnostic potential with key manuscript publication","url":"https://stock-news.laohu8.com/highlight/detail?id=2504290702","media":"Grafa","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2504290702?lang=en_us&edition=full_marsco","pubTime":"2025-01-17 13:45","pubTimestamp":1737092707,"startTime":"0","endTime":"0","summary":"Memphasys  has announced the acceptance of a key manuscript, detailing the capabilities of its RoXsta system, in the journal Antioxidants.The advancement showcases the commercial and scientific potential of RoXsta, a diagnostic platform designed to address oxidative stress across various biological applications.The study, co-authored by Memphasys' Scientific Director, Laureate Professor John Aitken, alongside researchers from the University of Newcastle, highlights the RoXsta system's ability to accurately profile oxidative stress in human and animal samples.The publication emphasises RoXsta's role in addressing conditions linked to oxidative stress, including infertility, cardiovascular diseases, neurodegenerative disorders, and cancer.David Ali, Managing Director and CEO of Memphasys, commented, \"This publication is a testament to RoXsta’s transformative capabilities. Its diagnostic power not only reinforces Memphasys’ leadership in reproductive health but also positions us for broad","market":null,"thumbnail":"https://images.grafa.com/grafa/media-health-memphasys-highlights-roxsta-s-diagnostic-potential-with-key-manuscript-publication-349903-638726895079808562.jpeg","type":0,"news_type":0,"thumbnails":["https://images.grafa.com/grafa/media-health-memphasys-highlights-roxsta-s-diagnostic-potential-with-key-manuscript-publication-349903-638726895079808562.jpeg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://grafa.com/news/health-memphasys-highlights-roxsta-s-diagnostic-potential-with-key-manuscript-publication-349903?referralcode=A314DFDBE96C354756A893C6E3E02493","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MEM.AU","BK7048"],"gpt_icon":0},{"id":"2503984990","title":"Memphasys Says Publication of Study Demonstrates Oxidative Stress Profiling System Potential","url":"https://stock-news.laohu8.com/highlight/detail?id=2503984990","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503984990?lang=en_us&edition=full_marsco","pubTime":"2025-01-16 10:44","pubTimestamp":1736995457,"startTime":"0","endTime":"0","summary":"Memphasys   said the publication of a study in the \"Antioxidants\" journal reinforces the commercial potential as well as the scientific credibility of its RoXsta platform to identify oxidative stress in human and animal samples, according to a Thursday Australian bourse filing.RoXsta is a proprietary antioxidant diagnostic platform for identifying oxidative stress-related deficiencies, and the study supports its ability to diagnose oxidative stress through analysis of biological fluids, the filing added.The RoXsta system has potential for male infertility treatments as well as disease management in conditions such as neurodegenerative diseases, cardiovascular disorders, and cancer, the filing said.It is also exploring its potential for the optimization of livestock productivity by mitigating oxidative stress.Oxidative stress is linked to infertility, cardiovascular disease, neurodegenerative disorders, cancer, and other conditions, the filing said.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["MEM.AU","BK7048","MEM"],"gpt_icon":0},{"id":"2503604638","title":"Publication highlights strengths of Memphasys’ antioxidant profiling system","url":"https://stock-news.laohu8.com/highlight/detail?id=2503604638","media":"The Market Herald","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503604638?lang=en_us&edition=full_marsco","pubTime":"2025-01-16 07:28","pubTimestamp":1736983680,"startTime":"0","endTime":"0","summary":"Memphasys Ltd  has seen a boost to its proprietary antioxidant profiling system RoXsta through the publication of a recent manuscript that emphasises its commercial potential and scientific credibility.The publication, ‘A Comparative Analysis of the Antioxidant Profiles Generated by the RoXsta System for Diverse Biological Fluids,’ appeared in the prestigious journal Antioxidants and was co-authored by Laureate Professor John Aitken, Memphasys’ scientific director, and a team of researchers from the University of Newcastle.Managing director and CEO of Memphasys David Ali said the manuscript was a testament to RoXsta’s transformative capabilities.“Its diagnostic power not only reinforces Memphasys’ leadership in reproductive health but also positions us for broader market opportunities in livestock and clinical applications.Join the discussion:See what HotCopperusers are saying aboutMemphasys Ltd and be part of the conversations that move the markets.The material provided in this articl","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://themarketonline.com.au/publication-highlights-strengths-of-memphasys-antioxidant-profiling-system-2025-01-16/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"markerherald_stock","symbols":["BK7048","MEM","MEM.AU"],"gpt_icon":0},{"id":"2501475520","title":"Memphasys launches in vitro utilisation testing of Felix System in China","url":"https://stock-news.laohu8.com/highlight/detail?id=2501475520","media":"Grafa","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2501475520?lang=en_us&edition=full_marsco","pubTime":"2025-01-06 10:11","pubTimestamp":1736129465,"startTime":"0","endTime":"0","summary":"Memphasys  has commenced in vitro utilisation testing of its Felix System in China, under an agreement with Heranova Lifesciences HK.The testing takes place at Sichuan Jinxin Xinan Women & Children Hospital in Chengdu, a significant step in validating the Felix System's usability in China's extensive assisted reproductive treatment market.Heranova will lead the testing, assessing the system's performance across 50 IVF cases.The evaluation covers both the biological performance of improving key sperm parameters and exploring health economic benefits like cost savings and ease of use.David Ali, Managing Director and CEO of Memphasys, said, \"The commencement of utilisation testing with Heranova represents a critical step in establishing the Felix System's presence in Greater China. This milestone reinforces our commitment to bringing innovative solutions to global markets.\". Frank Zhang, Vice President of Medical at Heranova, added, \"The Felix System aligns perfectly with our mission to a","market":null,"thumbnail":"https://images.grafa.com/grafa/media-health-memphasys-launches-in-vitro-utilisation-testing-of-felix-system-in-china-343216-638717262650145372.jpeg","type":0,"news_type":0,"thumbnails":["https://images.grafa.com/grafa/media-health-memphasys-launches-in-vitro-utilisation-testing-of-felix-system-in-china-343216-638717262650145372.jpeg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://grafa.com/news/health-memphasys-launches-in-vitro-utilisation-testing-of-felix-system-in-china-343216?referralcode=A314DFDBE96C354756A893C6E3E02493","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7048","MEM.AU"],"gpt_icon":0},{"id":"2501426779","title":"Memphasys to Start Utilization Testing of Reproductive Biotechnology Product in China","url":"https://stock-news.laohu8.com/highlight/detail?id=2501426779","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2501426779?lang=en_us&edition=full_marsco","pubTime":"2025-01-06 09:07","pubTimestamp":1736125631,"startTime":"0","endTime":"0","summary":"Memphasys  will start in vitro utilization testing of its Felix System in China as part of an agreement with Hong Kong-based biotech company Heranova Lifesciences HK, according to a Monday filing with the Australian bourse.Heranova will conduct testing at Sichuan Jinxin Xinan Women & Children Hospital in Chengdu to assess the usability of the system in routine and challenging in vitro fertilization cases using 50 patient cases, with the company supplying 50 Felix cartridges and one console, the filing said.The testing will assess the biological performance and health economic benefits of the system, according to the filing.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7048","MEM.AU","MEM"],"gpt_icon":0},{"id":"2492435888","title":"Memphasys starts study on RoXsta System to improve cattle reproduction","url":"https://stock-news.laohu8.com/highlight/detail?id=2492435888","media":"Grafa","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492435888?lang=en_us&edition=full_marsco","pubTime":"2024-12-20 07:01","pubTimestamp":1734649281,"startTime":"0","endTime":"0","summary":"Memphasys  has commenced a study to explore the RoXsta antioxidant system's potential in identifying oxidative stress thresholds in cattle and their correlation with reproductive performance.The study aims to advance understanding of oxidative stress's impact on livestock fertility, critical to enhancing agricultural productivity.Blood samples have been collected successfully and are stored at -80°C, ensuring their quality for analysis.The vital phase sets the scene for comprehensive testing beginning in January 2025.Conducted in a commercial cattle setting in New South Wales, the study involves analysing samples from 50 heifers, obtained about a month after artificial insemination.David Ali, Managing Director and CEO of Memphasys, stated, \"We are pleased to confirm the timely collection and storage of these blood samples, a critical component in our assessment of the RoXsta System’s applications in agriculture.\". He emphasised the study's potential to pioneer innovative approaches wit","market":null,"thumbnail":"https://images.grafa.com/grafa/media-agriculture-memphasys-starts-study-on-roxsta-system-to-improve-cattle-reproduction-336039-638702460814251214.jpeg","type":0,"news_type":0,"thumbnails":["https://images.grafa.com/grafa/media-agriculture-memphasys-starts-study-on-roxsta-system-to-improve-cattle-reproduction-336039-638702460814251214.jpeg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://grafa.com/news/agriculture-memphasys-starts-study-on-roxsta-system-to-improve-cattle-reproduction-336039?referralcode=A314DFDBE96C354756A893C6E3E02493","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MEM.AU","BK7048"],"gpt_icon":0},{"id":"2492921661","title":"Memphasys completes patient recruitment for Felix System trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2492921661","media":"Grafa","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492921661?lang=en_us&edition=full_marsco","pubTime":"2024-12-18 13:08","pubTimestamp":1734498510,"startTime":"0","endTime":"0","summary":"Memphasys  has completed patient recruitment for the clinical trial of its innovative Felix System.The trial, conducted in collaboration with Monash IVF Group, sets the stage for the finalisation of data analysis, which is crucial for expanding the product's market presence.David Ali, Managing Director and CEO of Memphasys highlighted, \"Completion of the Felix registration study marks a commercially transformative milestone for Memphasys.\". \"I would like to thank all who have been involved in the development of the sperm separation Felix System, particularly our shareholders who have made this possible,\" Ali added.Professor Rob McLachlan of Monash IVF Group noted, \"The process of isolating healthy sperm is essential in assisted reproduction treatment. With this trial, we hope to show that FelixTM System is a far more efficient way of separating sperm.\". The company is preparing for regulatory and commercial engagement in existing and new markets, with notable traction already observed ","market":null,"thumbnail":"https://images.grafa.com/grafa/media-health-memphasys-completes-patient-recruitment-for-felix-system-trial-334187-638700953106719100.jpeg","type":0,"news_type":0,"thumbnails":["https://images.grafa.com/grafa/media-health-memphasys-completes-patient-recruitment-for-felix-system-trial-334187-638700953106719100.jpeg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://grafa.com/news/health-memphasys-completes-patient-recruitment-for-felix-system-trial-334187?referralcode=A314DFDBE96C354756A893C6E3E02493","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7048","MEM.AU"],"gpt_icon":0},{"id":"2490142843","title":"BRIEF-Memphasys Signs Letter Of Intent With Heranova","url":"https://stock-news.laohu8.com/highlight/detail?id=2490142843","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490142843?lang=en_us&edition=full_marsco","pubTime":"2024-12-12 09:03","pubTimestamp":1733965404,"startTime":"0","endTime":"0","summary":"Dec 12 (Reuters) - Memphasys Ltd   :   * SIGNS LETTER OF INTENT WITH HERANOVA FOR FELIXTM SYSTEM DISTRIBUTION IN GREATER CHINA Further company coverage:    ((Reuters.Briefs@thomsonreuters.com;))","market":null,"thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MEM.AU","BK7048"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.memphasys.com","stockEarnings":[{"period":"1week","weight":0},{"period":"1month","weight":-0.4444},{"period":"3month","weight":-0.1667},{"period":"6month","weight":-0.2857},{"period":"1year","weight":-0.375},{"period":"ytd","weight":-0.375}],"compareEarnings":[{"period":"1week","weight":0.0159},{"period":"1month","weight":-0.0169},{"period":"3month","weight":0.0469},{"period":"6month","weight":0.095},{"period":"1year","weight":0.1651},{"period":"ytd","weight":0.0889}],"compareStock":{"symbol":"F100.AU","name":"BETASHARES FTSE 100 ETF"},"description":"Memphasys Limited, a bio-separations company, develops, manufactures, and sells cell and protein separation devices, and related consumables for the healthcare, veterinary, and biotechnology market sectors in Australia. It primarily develops Felix that separates sperm from semen sample using electrophoresis and specialist membranes for the use in fertility treatments, including IVF for humans, as well as for artificial reproductive techniques for animals; and a polymer membrane separation technology using polyacrylamide hydrogel membranes with electrophoresis. The company was formerly known as NuSep Holdings Limited and changed its name to Memphasys Limited in July 2016. Memphasys Limited is headquartered in Homebush, Australia.","yearOnYearQuotes":[{"month":1,"riseRate":0.222222,"avgChangeRate":-0.066366},{"month":2,"riseRate":0.555556,"avgChangeRate":0.034895},{"month":3,"riseRate":0.352941,"avgChangeRate":-0.029251},{"month":4,"riseRate":0.3125,"avgChangeRate":-0.026217},{"month":5,"riseRate":0.294118,"avgChangeRate":-0.10002},{"month":6,"riseRate":0.5,"avgChangeRate":0.270016},{"month":7,"riseRate":0.277778,"avgChangeRate":-0.019193},{"month":8,"riseRate":0.277778,"avgChangeRate":-0.079312},{"month":9,"riseRate":0.388889,"avgChangeRate":0.151618},{"month":10,"riseRate":0.333333,"avgChangeRate":-0.01723},{"month":11,"riseRate":0.411765,"avgChangeRate":0.046122},{"month":12,"riseRate":0.388889,"avgChangeRate":-0.107584}],"exchange":"ASX","name":"Memphasys","nameEN":"Memphasys"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.33.2","shortVersion":"4.33.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Memphasys(MEM.AU),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Memphasys(MEM.AU) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Memphasys,MEM.AU,Memphasys股票,Memphasys股票老虎,Memphasys股票老虎国际,Memphasys行情,Memphasys股票行情,Memphasys股价,Memphasys股市,Memphasys股票价格,Memphasys股票交易,Memphasys股票购买,Memphasys股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Memphasys(MEM.AU),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Memphasys(MEM.AU) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}